Acute Myeloid Leukemia Excellence Forum

Acute Myeloid Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Guenther Koehne, MD, PhD, Miami Cancer Institute

Podcasts

Therapeutic Advances and Considerations for Treatment Selection in High-Risk AML

04/13/2022

Guenther Koehne, MD, PhD, interviews Richard Stone, MD; Robert Soiffer, MD; and Siddhartha Mukherjee, MD, on recent therapeutic advances for hematologic malignancies with a focus on considerations for treatment selection in high-risk AML.

Guenther Koehne, MD, PhD,...

04/13/2022

Oncology

Videos

Guenther Koehne, MD, PhD, Shares Details on New FDA-Approved Trials in AML

03/29/2022

Guenther Koehne, MD, PhD, highlights 2 new FDA-approved clinical trials, including a pilot study on CPX351 plus midostaurin followed by alloHSCT for AML and a phase 1 dose trial of lymphocyte infusions following CD34-selected alloHSCT for the...

Guenther Koehne, MD, PhD,...

03/29/2022

Oncology

Videos

Dr Uy Reviews Low-Dose CPX-351 Plus Venetoclax for AML

03/09/2022

Geoffrey L. Uy, MD, reviews the safety and efficacy results from a phase 1b study on lower-dose CPX-351 plus venetoclax as a first-line treatment for patients with AML who are unfit for intensive chemotherapy, presented at ASH 2021.

Geoffrey L. Uy, MD, reviews the...

03/09/2022

Oncology

Videos

GVHD Outcomes of Busulfan Plus Fludarabine for Older Patients With Hematologic Malignancies

03/03/2022

Uday R Popat, MD, overviews the long-term disease outcomes from a phase 2 prospective clinical trial on myeloablative fractionated busulfan with fludarabine in older patients with hematologic malignancies.

Uday R Popat, MD, overviews the...

03/03/2022

Oncology

Videos

Orca-T Demonstrates Reduced Instances of GVHD for Hematologic Malignancies

01/24/2022

Dr Meyer on how Orca-T, an investigational cell therapy, led to high GVHD- and relapse-free survival following myeloablative conditioning for hematologic malignancies, presented at ASH 2021.

Dr Meyer on how Orca-T, an...

01/24/2022

Oncology

Videos

Dr Jamy Highlights HMAs Plus Venetoclax for Patients With R/R AML

01/18/2022

Omer Hassan Jamy, MD, highlights a retrospective study on HMAs plus venetoclax versus intensive chemotherapy for patients with R/R AML. These data were presented at the 2021 ASH Annual Meeting.

Omer Hassan Jamy, MD, highlights...

01/18/2022

Oncology

Videos

Dr Lee Highlights the Treatment Landscape for Patients With MDS, AML

11/29/2021

Sangmin Lee, MD, highlights the current treatment landscape for patients with MDS, including novel therapies that are in development in combination with hypomethylating agents.

Sangmin Lee, MD, highlights the...

11/29/2021

Oncology

Podcasts

Tapan Kadia, MD, Highlights Venetoclax Plus Chemotherapy for AML, MDS

11/11/2021

Tapan M. Kadia, MD, highlights a phase 2 trial on venetoclax plus intensive chemotherapy in patients with newly diagnosed AML or MDS.

Tapan M. Kadia, MD, highlights a...

11/11/2021

Oncology

Videos

Triplet Combo Highly Active in Relapsed/Refractory FLT3-Mutated AML

11/03/2021

Musa Yilmaz, MD, discusses a highly active triplet combination for patients with FLT3-ITD mutated AML. These data were presented at the 2021 ASCO Annual Meeting.

Musa Yilmaz, MD, discusses a...

11/03/2021

Oncology

Videos

Dr Azab Highlights Nanoparticle T Cell Engagers for Patients With AML

10/22/2021

Kareem Azab, PhD, Washington University, highlights nanoparticle T cell engagers for the treatment of patients with AML.

Kareem Azab, PhD, Washington...

10/22/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology